Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.

David Schenkein, a general partner at GV and a seasoned hematologist, shares insights from his journey in biotech. He discusses the importance of company culture and how his diverse background shaped his investment philosophy. Schenkein emphasizes embracing failure as a vital part of innovation and reveals the interplay between AI and drug discovery. He reflects on his transition from CEO to venture capitalist, underlining the need for diverse strategies in investing. His vision focuses on patient outcomes and the transformative potential of biotech advancements.

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.

Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.

Chris Garcia, a biochemistry professor at Stanford and biotech entrepreneur, dives into the fascinating world of protein engineering for cancer and autoimmune treatments. He shares his transformative journey from aspiring tennis player to leading immunology research. Topics include the ingenious application of AI in protein design, innovative strategies for enhancing clinical trials, and the significance of T-cell interactions in cancer therapies. Personal anecdotes of endurance running cleverly illustrate how these experiences spark creative breakthroughs in science.

Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.